Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Immuneering (Nasdaq: IMRX) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. Enrollment progressing well in IMM-1-104 Phase 2a trial, with initial data from multiple arms expected in 2H 2024.
2. FDA Fast Track Designation granted for IMM-1-104 in first-line pancreatic cancer.
3. Preclinical data presented at AACR showing IMM-1-104 combined with chemotherapies yields deeper tumor growth inhibition in pancreatic cancer models.
4. Initial PK, PD, and safety data from IMM-6-415 Phase 1/2a trial expected in 2H 2024.
Financial highlights: Cash position of $59.7 million as of June 30, 2024. Q2 2024 R&D expenses were $10.7 million, G&A expenses were $4.3 million, and net loss was $14.1 million ($0.47 per share). Cash runway expected to fund operations into 2H 2025.
Immuneering (Nasdaq: IMRX) ha riportato i risultati finanziari per il secondo trimestre del 2024 e ha fornito aggiornamenti aziendali. Punti salienti includono:
1. Il reclutamento procede bene nell'ambito dello studio clinico di fase 2a IMM-1-104, con dati iniziali provenienti da più bracci attesi nel secondo semestre del 2024.
2. Designazione di Fast Track concessa dalla FDA per IMM-1-104 nel trattamento del cancro pancreatico di prima linea.
3. Dati preclinici presentati all'AACR mostrano che IMM-1-104 combinato con chemioterapia porta a una più profonda inibizione della crescita tumorale nei modelli di cancro pancreatico.
4. Dati iniziali di farmacocinetica, farmacodinamica e sicurezza dello studio clinico di fase 1/2a IMM-6-415 attesi nel secondo semestre del 2024.
Punti salienti finanziari: Posizione di cassa di 59,7 milioni di dollari al 30 giugno 2024. Le spese per ricerca e sviluppo del secondo trimestre del 2024 sono state di 10,7 milioni di dollari, le spese generali e amministrative di 4,3 milioni di dollari, e la perdita netta è stata di 14,1 milioni di dollari (0,47 dollari per azione). Si prevede che la liquidità disponibile sostenga le operazioni fino al secondo semestre del 2025.
Immuneering (Nasdaq: IMRX) reportó los resultados financieros del segundo trimestre de 2024 y dio actualizaciones sobre el negocio. Los aspectos más destacados incluyen:
1. El reclutamiento avanza bien en el ensayo de fase 2a IMM-1-104, con datos iniciales de múltiples grupos esperados en la segunda mitad de 2024.
2. Designación de Fast Track otorgada por la FDA para IMM-1-104 en cáncer de páncreas de primera línea.
3. Datos preclínicos presentados en AACR que muestran que IMM-1-104 combinado con quimioterapias produce una inhibición más profunda del crecimiento tumoral en modelos de cáncer de páncreas.
4. Se esperan datos iniciales de PK, PD y seguridad del ensayo de fase 1/2a IMM-6-415 en la segunda mitad de 2024.
Aspectos financieros destacados: Posición de efectivo de 59.7 millones de dólares al 30 de junio de 2024. Los gastos de I+D del segundo trimestre de 2024 fueron de 10.7 millones de dólares, los gastos generales y administrativos fueron de 4.3 millones de dólares, y la pérdida neta fue de 14.1 millones de dólares (0.47 dólares por acción). Se espera que los fondos disponibles financien las operaciones hasta la segunda mitad de 2025.
Immuneering (NASDAQ: IMRX)는 2024년 2분기 재무 결과를 보고하고 비즈니스 업데이트를 제공했습니다. 주요 내용은 다음과 같습니다:
1. IMM-1-104 2a 상도 시험에 대한 등록이 순조롭게 진행되고 있으며, 여러 그룹에서 초기 데이터가 2024년 하반기에 기대됩니다.
2. 1차 췌장암에 대한 IMM-1-104에 대해 FDA의 신속 승인 절차가 승인되었습니다.
3. AACR에서 발표된 전임상 데이터에 따르면, IMM-1-104가 화학요법과 결합될 경우 췌장암 모델에서 종양 성장 억제 효과가 더욱 깊어지는 것으로 나타났습니다.
4. IMM-6-415 1/2a 상도 시험에서 초기 약동학, 약역학 및 안전성 데이터가 2024년 하반기에 기대됩니다.
재무 하이라이트: 2024년 6월 30일 기준 현금 보유액은 5,970만 달러입니다. 2024년 2분기 연구개발비는 1,070만 달러, 일반관리비는 430만 달러였으며, 순손실은 1,410만 달러(주당 0.47달러)였습니다. 현금 흐름은 2025년 하반기까지 운영 자금을 지원할 것으로 예상됩니다.
Immuneering (Nasdaq: IMRX) a annoncé ses résultats financiers du deuxième trimestre 2024 et a fourni des mises à jour sur l'entreprise. Les points forts incluent:
1. Le recrutement progresse bien dans l'essai de phase 2a IMM-1-104, avec des données initiales de plusieurs bras attendus au deuxième semestre de 2024.
2. Désignation Fast Track accordée par la FDA pour IMM-1-104 dans le traitement du cancer du pancréas en première ligne.
3. Des données précliniques présentées à l'AACR montrent qu'IMM-1-104 combiné avec des chimiothérapies entraîne une inhibition plus profonde de la croissance tumorale dans des modèles de cancer du pancréas.
4. Des données initiales sur la PK, la PD et la sécurité de l'essai de phase 1/2a IMM-6-415 sont attendues au deuxième semestre 2024.
Points financiers clés: Position de trésorerie de 59,7 millions de dollars au 30 juin 2024. Les dépenses R&D du deuxième trimestre 2024 étaient de 10,7 millions de dollars, les dépenses générales et administratives de 4,3 millions de dollars et la perte nette s'élevait à 14,1 millions de dollars (0,47 dollar par action). La trésorerie disponible devrait financer les opérations jusqu'au deuxième semestre 2025.
Immuneering (Nasdaq: IMRX) hat die Finanzzahlen für das zweite Quartal 2024 veröffentlicht und Unternehmensupdates gegeben. Wichtige Highlights sind:
1. Die Rekrutierung verläuft gut in der Phase 2a-Studie IMM-1-104, mit ersten Daten aus mehreren Armstudien, die im zweiten Halbjahr 2024 erwartet werden.
2. Die FDA hat die Fast Track-Bezeichnung für IMM-1-104 bei Erstlinien-Pankreaskrebs erteilt.
3. Vorliminary Daten, die auf der AACR präsentiert wurden, zeigen, dass IMM-1-104 in Kombination mit Chemotherapien eine tiefere Hemmung des Tumorwachstums in Pankreaskrebsmodellen bewirkt.
4. Erste PK-, PD- und Sicherheitsdaten der Phase 1/2a-Studie IMM-6-415 werden im zweiten Halbjahr 2024 erwartet.
Finanzielle Highlights: Liquidität von 59,7 Millionen US-Dollar zum 30. Juni 2024. Die F&E-Ausgaben für das zweite Quartal 2024 betrugen 10,7 Millionen US-Dollar, die Gemeinkosten 4,3 Millionen US-Dollar und der Nettoverlust 14,1 Millionen US-Dollar (0,47 US-Dollar pro Aktie). Die finanzielle Deckung wird voraussichtlich die Betriebe bis zum zweiten Halbjahr 2025 sichern.
- FDA Fast Track Designation granted for IMM-1-104 in first-line pancreatic cancer
- Enrollment progressing well in IMM-1-104 Phase 2a trial across all arms
- Preclinical data shows IMM-1-104 combined with chemotherapies yields deeper tumor growth inhibition in pancreatic cancer models
- Initial data from multiple arms of IMM-1-104 Phase 2a trial expected in 2H 2024
- Initial PK, PD, and safety data from IMM-6-415 Phase 1/2a trial expected in 2H 2024
- Cash runway expected to fund operations into second half of 2025
- Net loss increased to $14.1 million in Q2 2024 from $12.2 million in Q2 2023
- R&D expenses increased to $10.7 million in Q2 2024 from $9.5 million in Q2 2023
- G&A expenses increased to $4.3 million in Q2 2024 from $4.0 million in Q2 2023
- Cash position decreased to $59.7 million as of June 30, 2024, from $85.7 million as of December 31, 2023
Insights
Immuneering's Q2 2024 financials reveal a cash position of
Immuneering's IMM-1-104 shows promise in multiple cancer types. The FDA Fast Track designation for first-line pancreatic cancer is significant, potentially expediting development and review. Preclinical data demonstrating synergy with chemotherapy in pancreatic cancer models is encouraging. The ongoing Phase 2a trial, with initial data expected in 2H 2024, could be a pivotal moment. The IMM-6-415 program targeting RAF/RAS mutations adds depth to the pipeline. However, it's important to note that while shrinkage in target lesions was observed in
Immuneering's focus on RAS/RAF mutations positions it in a highly competitive yet potentially lucrative market. The pancreatic cancer indication, with its poor prognosis and treatment options, represents a significant unmet need. The company's approach of combining IMM-1-104 with established chemotherapies could provide a strategic advantage if successful. However, investor sentiment may be tempered by the extended timeline to meaningful clinical data and the company's financial position. The projected cash runway into 2H 2025 may not be sufficient to reach key value-inflection points, potentially necessitating dilutive financing. Market reaction will likely hinge on the robustness of the upcoming data readouts in 2H 2024.
- Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 -
- Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer -
- Preclinical Data Presented at AACR Demonstrates that Combining IMM-1-104 with Chemotherapies Used in the Treatment of First-line Pancreatic Cancer Yields Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone -
- Initial PK, PD and Safety Data from Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations expected in 2H 2024 -
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided business updates.
“Our IMM-1-104 Phase 2a trial is enrolling well across all arms, and we are on track to share initial data from multiple arms this year,” said Ben Zeskind, Ph.D., Co-founder, and Chief Executive Officer of Immuneering. “Each arm represents an important unmet need, including first-line pancreatic cancer patients, which are the focus of both our recent Fast Track designation and multiple arms of the trial, including two arms evaluating IMM-1-104 in combination with established chemotherapy regimens. As we reported at AACR in April, these combinations in animal models showed deeper and more durable tumor growth inhibition than either treatment alone. We believe these arms are also of interest because of the Phase 1 topline data we released in March, in which IMM-1-104 monotherapy was observed to be exceptionally well-tolerated and shrank at least one target lesion in about half of pancreatic cancer patients. We are also evaluating IMM-1-104 in monotherapy arms for patients with RAS mutant melanoma and RAS mutant lung cancer, cancer types for which IMM-1-104 has demonstrated encouraging preclinical data, along with a monotherapy arm evaluating IMM-1-104 in first and second-line pancreatic cancer patients. Finally, the Phase 1 dose escalation of IMM-6-415 is progressing well in patients with advanced solid tumors with RAF or RAS mutations, and we plan to report initial PK, PD and safety data this year. All in all, we are looking forward to a data-rich second half of 2024.”
Corporate Highlights
- FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer: In July 2024, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for IMM-1-104, as a first-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC).
- Preclinical Data Presented at AACR Demonstrating that IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models: In April 2024, Immuneering presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting, demonstrating that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either treatment alone, which the Company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors.
Near-Term Milestone Expectations
IMM-1-104
- Initial data from multiple arms of the Phase 2a portion of the Company’s Phase 1/2a trial expected in 2H 2024.
IMM-6-415
- Initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data from the Phase 1 portion of the Company’s Phase 1/2a trial expected in 2H 2024.
Second Quarter 2024 Financial Highlights
Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2024 were
Research and Development (R&D) Expenses: R&D expenses for the second quarter of 2024, were
General and Administrative (G&A) Expenses: G&A expenses for the second quarter of 2024 were
Net Loss: Net loss attributable to common stockholders was
2024 Financial Guidance
Based on cash and cash equivalents as of June 30, 2024, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into the second half of 2025.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The Company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.
Forward-Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: Immuneering’s plans to develop, manufacture and commercialize its product candidates; the sufficiency of the Company’s cash, cash equivalents, and cash runway; its current operating plans; the treatment potential of IMM-1-104 and IMM-6-415, alone or in combination with other agents, including the ability to shrink tumors in a well-tolerated way relative to other MAPK pathway inhibitors; the design, enrollment criteria and progress of the Phase 1/2a clinical trials of IMM-1-104 and IMM-6-415; the translation of preclinical data into human clinical data; the potential advantages and effectiveness of Immuneering’s clinical and preclinical candidates; and the pace of enrollment and timing of reporting data from the Phase 2a portion of the trial for IMM-1-104 and from the Phase 1 portion of the trial for IMM-6-415.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements (or timing thereof) to be materially different from any future results, performance or achievements (or timing thereof) expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results (or timing thereof) to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Media Contact:
Gina Nugent
gina@nugentcommunications.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
IMMUNEERING CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||
Operating expenses | |||||||||||||||
Research and development | 10,651,958 | 9,452,711 | 21,854,372 | 19,663,637 | |||||||||||
General and administrative | 4,254,473 | 4,044,960 | 8,370,493 | 8,506,291 | |||||||||||
Amortization of intangible asset | 7,317 | 7,317 | 14,633 | 14,633 | |||||||||||
Total operating expenses | 14,913,748 | 13,504,988 | 30,239,498 | 28,184,561 | |||||||||||
Loss from operations | (14,913,748 | ) | (13,504,988 | ) | (30,239,498 | ) | (28,184,561 | ) | |||||||
Other income (expense) | |||||||||||||||
Interest income | 826,104 | 1,166,047 | 1,630,988 | 1,997,321 | |||||||||||
Other income, net | 7,717 | 150,193 | 220,754 | 394,322 | |||||||||||
Net loss | $ | (14,079,927 | ) | $ | (12,188,748 | ) | $ | (28,387,756 | ) | $ | (25,792,918 | ) | |||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.47 | ) | $ | (0.43 | ) | $ | (0.96 | ) | $ | (0.94 | ) | |||
Weighted-average common shares outstanding, basic and diluted | 29,653,355 | 28,647,450 | 29,511,856 | 27,550,922 | |||||||||||
Other comprehensive loss: | |||||||||||||||
Unrealized gains (losses) from marketable securities | 1,084 | (2,724 | ) | 778 | 27,902 | ||||||||||
Comprehensive Loss | $ | (14,078,843 | ) | $ | (12,191,472 | ) | $ | (28,386,978 | ) | $ | (25,765,016 | ) |
IMMUNEERING CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) | |||||||
June 30, 2024 | December 31, 2023 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 59,728,455 | $ | 59,405,817 | |||
Marketable securities | — | 26,259,868 | |||||
Prepaids and other current assets | 3,957,220 | 3,417,984 | |||||
Total current assets | 63,685,675 | 89,083,669 | |||||
Property and equipment, net | 1,290,091 | 1,400,582 | |||||
Goodwill | 6,690,431 | 6,690,431 | |||||
Intangible asset, net | 365,047 | 379,680 | |||||
Right-of-use assets, net | 3,827,943 | 3,995,730 | |||||
Other assets | 1,228,088 | 1,034,446 | |||||
Total assets | $ | 77,087,275 | $ | 102,584,538 | |||
Liabilities and Stockholders' Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 2,622,237 | $ | 2,111,666 | |||
Accrued expenses | 3,757,148 | 5,173,960 | |||||
Other liabilities | 90,242 | 259,770 | |||||
Lease liabilities | 311,459 | 300,107 | |||||
Total current liabilities | 6,781,086 | 7,845,503 | |||||
Long-term liabilities: | |||||||
Lease liabilities, net of current portion | 4,000,554 | 4,162,852 | |||||
Total liabilities | 10,781,640 | 12,008,355 | |||||
Commitments and contingencies (Note 10) | |||||||
Stockholders’ equity: | |||||||
Preferred stock, | — | — | |||||
Class A common stock, | 29,653 | 29,272 | |||||
Class B common stock, | — | — | |||||
Additional paid-in capital | 257,922,316 | 253,806,267 | |||||
Accumulated other comprehensive loss | — | (778 | ) | ||||
Accumulated deficit | (191,646,334 | ) | (163,258,578 | ) | |||
Total stockholders' equity | 66,305,635 | 90,576,183 | |||||
Total liabilities and stockholders' equity | $ | 77,087,275 | $ | 102,584,538 |
FAQ
What is the current status of Immuneering's (IMRX) IMM-1-104 Phase 2a trial?
Has Immuneering (IMRX) received any FDA designations for IMM-1-104?
What were Immuneering's (IMRX) financial results for Q2 2024?
When does Immuneering (IMRX) expect to report initial data from the IMM-6-415 trial?